TL;DR:

• The General Pharmaceutical Council has published its first formal position statement on AI, confirming that pharmacy teams using AI tools must do so in line with existing professional standards rather than new AI-specific rules.
• The statement makes clear that pharmacists and pharmacy technicians “remain personally accountable for their professional practice, even when AI is being used” — with obligations to review outputs for accuracy and bias, seek patient consent, and explain AI use in patient care.
• Pharmacy owners are expected to maintain governance, training and monitoring arrangements; AI-generated revalidation submissions are explicitly prohibited and may trigger investigation.

The GPhC joins a widening patchwork of UK professional regulators — the General Medical Council, Nursing and Midwifery Council and now the pharmacy body — issuing AI position statements rather than waiting for central AI regulation. The pattern is consistent: accountability stays with the human professional, AI is framed as a tool, and detailed compliance obligations are deliberately pushed into existing standards rather than into a new AI rulebook.

What is actually new in the GPhC statement

Three things distinguish the GPhC position from the medical regulators’ earlier guidance. First, the explicit prohibition on using AI to generate revalidation submissions — with an enforcement consequence attached — is stricter than the NMC or GMC positions and reflects specific regulator concern about falsified CPD records. Second, the patient-consent expectation is framed as a default: patients should be told when AI is used in their care, not just when it materially influences decisions. Third, the employer-level obligations on pharmacy owners — governance, monitoring, risk management — are spelled out rather than left implicit, which matters for multiple-pharmacy groups operating at scale.

The UK regulatory patchwork pattern

This fits the broader UK approach: rather than waiting for a horizontal AI Act, each sector regulator issues principle-based guidance anchored to its existing standards. The upside is speed — pharmacy gets workable rules now rather than in three years. The downside is inconsistency: a pharmacy professional moving between a community pharmacy, a hospital trust and an NHS primary-care network may face three different AI governance frameworks. The GPhC says it is working with other regulators and organisations on alignment, but no cross-regulator AI standard yet exists in UK healthcare.

Looking forward

The Royal College of Pharmacy, which published its own AI policy in January 2025, welcomed the statement. The more interesting near-term development is the GPhC’s commitment to further work “as part of the reviews of the standards we set for pharmacists and pharmacy technicians and our standards for registered pharmacies”. That signals AI-specific criteria will be baked into the next version of the core professional standards — a much harder shift for the sector to ignore than a standalone position statement. Pharmacy AI vendors targeting the UK market should expect tighter procurement diligence questions about consent workflows and explainability from mid-2026 onwards.